Therapy

Home-based Physical Therapy Provider PT Genie Opens Orlando Headquarters

Friday, May 29, 2020 - 7:00pm

ORLANDO, Fla., May 29, 2020 /PRNewswire-PRWeb/ -- PT Genie , a digital health company that is advancing the field of physical therapy with a system that keeps patients and providers connected online, will open its new headquarters in Orlando, Florida, June 1, 2020.

Key Points: 
  • ORLANDO, Fla., May 29, 2020 /PRNewswire-PRWeb/ -- PT Genie , a digital health company that is advancing the field of physical therapy with a system that keeps patients and providers connected online, will open its new headquarters in Orlando, Florida, June 1, 2020.
  • PT Genie is a patented interactive physical therapy device that is used by doctors, therapists, and their patients both in the clinic setting and remotely.
  • Studies of post-operative patients showed they recovered 60% faster when using PT Genie than with traditional physical therapy alone.
  • PT Genie is a digital health company providing in-clinic and remote physical therapy that keeps patients connected with their providers to drive improved outcomes.

Genekam Plasma Therapy Accelerator: a New solution for Better Antibody Therapy for All Coronavirus Patients

Friday, May 29, 2020 - 2:30pm

This will solve the shortage problem also of therapy as millions of persons recovered from coronavirus 2020 can donate the plasma many times a year.

Key Points: 
  • This will solve the shortage problem also of therapy as millions of persons recovered from coronavirus 2020 can donate the plasma many times a year.
  • SARS-Hunter is a quickest solution for creation of effective antibodies therapy with low costs for all patients around the world.
  • View the full release here: https://www.businesswire.com/news/home/20200529005307/en/
    Plasma Therapy Accelerator: a New Solution for Better Antibody Therapy for All Coronavirus Patients (Photo: Business Wire)
    Plasma from coronavirus recovered patients is being used as one of the successful therapeutic options to treat the corona virus-infected patients because it is rich in corona virus-specific antibodies.
  • SARS-hunter can have a very strong impact on the antibody therapy and should make available antibody therapy to a large population.

Update on Talaris’ Phase 2 Study of FCR001 in Living Donor Kidney Transplant Recipients to be Presented at ATC Virtual Congress

Friday, May 29, 2020 - 1:00pm

The data show that 26 of 37 (70%) of LDKT recipients of FCR001 were able to be weaned off all of their immunosuppression treatments.

Key Points: 
  • The data show that 26 of 37 (70%) of LDKT recipients of FCR001 were able to be weaned off all of their immunosuppression treatments.
  • The degree of HLA mismatch (spanning 0/6 to 6/6) between the donor and the recipient did not affect either the safety or the efficacy of the therapy.
  • FCR001 has received both Orphan Drug Designation and Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. Food and Drug Administration.
  • A Phase 3 trial of FCR001 in living donor kidney transplant recipients is now enrolling patients.

Nabriva Therapeutics Receives Positive EU CHMP Opinion for XENLETA™ (lefamulin) for the Treatment of Community-Acquired Pneumonia (CAP)

Friday, May 29, 2020 - 1:00pm

XENLETA has a novel mechanism of action and provides an urgently needed short course, empiric monotherapy treatment alternative for adult patients with CAP.

Key Points: 
  • XENLETA has a novel mechanism of action and provides an urgently needed short course, empiric monotherapy treatment alternative for adult patients with CAP.
  • The U.S. Food and Drug Administration (FDA) approved XENLETA in August 2019 for the treatment of adult patients with community-acquired bacterial pneumonia (CABP).
  • Nabriva Therapeutics received U.S. Food and Drug Administration approval for XENLETA (lefamulin injection, lefamulin tablets), the first systemic pleuromutilin antibiotic for community-acquired bacterial pneumonia (CABP).
  • XENLETA (lefamulin) is a first-in-class semi-synthetic pleuromutilin antibiotic for systemic administration in humans discovered and developed by the Nabriva Therapeutics team.

Iovance Presents Updated Clinical Data for Tumor Infiltrating Lymphocyte (TIL) Therapy Lifileucel in Advanced Melanoma at ASCO Scientific Program

Friday, May 29, 2020 - 1:01pm

We are very pleased to present the long term follow up data for lifileucel in melanoma at the ASCO Scientific Program, said Maria Fardis, Ph.D., President and Chief Executive Officer of Iovance Biotherapeutics.

Key Points: 
  • We are very pleased to present the long term follow up data for lifileucel in melanoma at the ASCO Scientific Program, said Maria Fardis, Ph.D., President and Chief Executive Officer of Iovance Biotherapeutics.
  • The median duration of response has not been reached at 18.7 months of study follow up supporting potential benefit of the one-time treatment of lifileucel TIL therapy in advanced melanoma patients.
  • Updated interim results from Cohort 2 are now available from an oral abstract session titled, Long-term follow up of lifileucel (LN-144) cryopreserved autologous tumor infiltrating lymphocyte therapy in patients with advanced melanoma progressed on multiple prior therapies.
  • A clinical study to investigate Iovance T cell therapy for blood cancers called peripheral blood lymphocyte (PBL) therapy is open to enrollment.

Vivos Inc Resumes IsoPet Animal Cancer Therapy

Friday, May 29, 2020 - 12:00pm

Richland WA, May 29, 2020 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Vivos Inc Resumes IsoPet Animal Cancer Therapy

Key Points: 
  • Richland WA, May 29, 2020 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Vivos Inc Resumes IsoPet Animal Cancer Therapy
    After several months of virus-related stand-down IsoPet therapy has been scheduled for the week of June 20.
  • Vivos Inc. has developed an Yttrium-90 based brachytherapy injectable device, for the treatment of tumors in animals (Isopet) and in humans (Radiogel).
  • The Isopet Solutions division is using university veterinary hospitals to demonstrate the safety and therapeutic effectiveness for different animal cancers.
  • Following this demonstration phase, Vivos can generate revenues through the sale of Isopet to University animal hospitals and private veterinary clinics.

Achilles Therapeutics doses first patient in Phase I/II Study in recurrent or metastatic malignant melanoma

Friday, May 29, 2020 - 12:00pm

Stevenage, UK 29 May 2020 Achilles Therapeutics (Achilles), a clinical stage biopharmaceutical company developing personalised cancer immunotherapies, today announced that it has dosed the first patient in a Phase I/II study of a clonal neoantigen T cell (cNeT) therapy in patients with recurrent or metastatic malignant melanoma.

Key Points: 
  • Stevenage, UK 29 May 2020 Achilles Therapeutics (Achilles), a clinical stage biopharmaceutical company developing personalised cancer immunotherapies, today announced that it has dosed the first patient in a Phase I/II study of a clonal neoantigen T cell (cNeT) therapy in patients with recurrent or metastatic malignant melanoma.
  • The THETIS study is an open-label, multi-centre Phase I/II trial evaluating the safety, tolerability and clinical efficacy of cNeT therapy as a single dose in patients with recurrent or metastatic malignant melanoma.
  • The dosing of our first melanoma patient with a cell therapy to specifically target all cancer cells, marks a significant milestone in delivering the first precision TIL therapy.
  • Achilles uses its proprietary process to manufacture T cells (cNeT) which exquisitely target a specific set of clonal neoantigens in each patient.

Achilles Therapeutics doses first patient in Phase I/II Study in recurrent or metastatic malignant melanoma

Friday, May 29, 2020 - 7:00am

Stevenage, UK 29 May 2020 Achilles Therapeutics (Achilles), a clinical stage biopharmaceutical company developing personalised cancer immunotherapies, today announced that it has dosed the first patient in a Phase I/II study of a clonal neoantigen T cell (cNeT) therapy in patients with recurrent or metastatic malignant melanoma.

Key Points: 
  • Stevenage, UK 29 May 2020 Achilles Therapeutics (Achilles), a clinical stage biopharmaceutical company developing personalised cancer immunotherapies, today announced that it has dosed the first patient in a Phase I/II study of a clonal neoantigen T cell (cNeT) therapy in patients with recurrent or metastatic malignant melanoma.
  • The THETIS study is an open-label, multi-centre Phase I/II trial evaluating the safety, tolerability and clinical efficacy of cNeT therapy as a single dose in patients with recurrent or metastatic malignant melanoma.
  • The dosing of our first melanoma patient with a cell therapy to specifically target all cancer cells, marks a significant milestone in delivering the first precision TIL therapy.
  • Achilles uses its proprietary process to manufacture T cells (cNeT) which exquisitely target a specific set of clonal neoantigens in each patient.

Clinical Studies & Research Progressing for Finding Cure for Glioblastoma

Thursday, May 28, 2020 - 2:00pm

Although there is no cure, there are treatments to help ease symptoms.

Key Points: 
  • Although there is no cure, there are treatments to help ease symptoms.
  • Additionally, clinical studies are providing better insight into how different cancers and cell types respond to treatment, allowing oncologists to recommend more effective therapies for each patient.
  • The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material.
  • You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements.

Clinical Studies & Research Progressing for Finding Cure for Glioblastoma

Thursday, May 28, 2020 - 2:00pm

Although there is no cure, there are treatments to help ease symptoms.

Key Points: 
  • Although there is no cure, there are treatments to help ease symptoms.
  • Additionally, clinical studies are providing better insight into how different cancers and cell types respond to treatment, allowing oncologists to recommend more effective therapies for each patient.
  • The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material.
  • You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements.